Amalgamated Bank Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Amalgamated Bank trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% in the second quarter, Holdings Channel.com reports. The institutional investor owned 21,438 shares of the biopharmaceutical company’s stock after selling 296 shares during the quarter. Amalgamated Bank’s holdings in Regeneron Pharmaceuticals were worth $22,532,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brown Lisle Cummings Inc. boosted its position in Regeneron Pharmaceuticals by 18.2% during the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 10 shares during the last quarter. Sachetta LLC raised its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the period. Team Hewins LLC raised its stake in Regeneron Pharmaceuticals by 2.5% during the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 11 shares during the period. Angeles Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 3.5% during the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 11 shares during the period. Finally, TrinityPoint Wealth LLC raised its stake in Regeneron Pharmaceuticals by 4.8% during the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 12 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the sale, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,026 shares of company stock valued at $11,498,705. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.5 %

REGN stock opened at $1,146.75 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20. The company has a market capitalization of $126.36 billion, a price-to-earnings ratio of 33.88, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12. The firm’s 50-day moving average is $1,128.09 and its two-hundred day moving average is $1,028.93. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period last year, the firm posted $8.79 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent analyst reports. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday. Finally, Barclays raised their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,111.30.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.